Acadia Pharmaceuticals
ACAD
320 hedge funds and large institutions have $2.87B invested in Acadia Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 63 funds opening new positions, 102 increasing their positions, 102 reducing their positions, and 37 closing their positions.
426% more call options, than puts
Call options by funds: $30.3M | Put options by funds: $5.77M
70% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 37
8% more funds holding
Funds holding: 296 → 320 (+24)
5.83% more ownership
Funds ownership: 97.88% → 103.71% (+5.8%)
0% more repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 102
4% less capital invested
Capital invested by funds: $2.99B → $2.87B (-$115M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$157M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$66.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$44.9M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$43.9M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$27.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$47.5M |
| 2 |
SG Americas Securities
New York
|
-$44.8M |
| 3 |
Man Group
London,
United Kingdom
|
-$18.6M |
| 4 |
Millennium Management
New York
|
-$18.5M |
| 5 |
D.E. Shaw & Co
New York
|
-$16.2M |
ACAD Hedge Fund Activity: Q1 2025 in Review
320 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q1 2025, worth a combined $2.87B — down 3.9% from $2.99B a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new ACAD positions and 37 closed out — a net gain of 26 holders — while 102 added to existing stakes and 102 trimmed.
The largest buyer was BlackRock, adding an estimated $157M. The largest seller was Morgan Stanley, cutting an estimated $47.5M.
- 320 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q1 2025, up from 296 in Q4 2024.
- Funds reported $2.87B of Acadia Pharmaceuticals stock for Q1 2025, down 3.9% quarter-over-quarter.
- 63 funds opened new Acadia Pharmaceuticals positions in Q1 2025 and 37 closed out, a net change of +26 holders.
- The largest Acadia Pharmaceuticals buyer in Q1 2025 was BlackRock, an estimated $157M added.
- The largest Acadia Pharmaceuticals seller in Q1 2025 was Morgan Stanley, an estimated $47.5M sold.
Based on aggregated 13F filings for Q1 2025.